Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma
CheckMate-142: Updated data from MSI high metastatic colon cancer patients
Advances in PARP inhibitor use for metastatic breast cancer
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer
The future of PARP inhibitors in metastatic breast cancer
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC
Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer
Managing metastatic breast cancer and beyond using PARP inhibitors
Updates in metastatic and early-stage breast cancer
PARP inhibitors in metastatic breast cancer: Where are we now?
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies